ProPhase Labs, Inc. Cash Provided by (Used in) Operating Activities, Discontinued Operations
ProPhase Labs, Inc. (PRPH) reported Cash Provided by (Used in) Operating Activities, Discontinued Operations of $597.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Cash Flow › Operating Activities
us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations · last filed 2026-08-19
- ProPhase Labs, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2025-12-31 was $0.00.
- ProPhase Labs, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2025-09-30 was $0.00.
- ProPhase Labs, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2025-06-30 was $0.00.
- ProPhase Labs, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2025-03-31 was $597.00K.
- ProPhase Labs, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2025 was $597.00K.
- ProPhase Labs, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2024 was -$5.74M, a 1980.33% decline from fiscal 2023.
- ProPhase Labs, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2023 was $305.00K.
| Period end | Cash Provided by (Used in) Operating Activities, Discontinued Operations 3 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 6 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 9 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $0.00 derived: sum of 2 quarters · filed 2026-06-01 | $0.00 derived: sum of 3 quarters · filed 2026-08-19 | $597.00K 10-K · filed 2026-06-01 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $0.00 derived: sum of 2 quarters · filed 2026-08-19 | $597.00K 10-Q · filed 2025-11-19 | $294.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $597.00K 10-Q · filed 2026-08-19 | $294.00K derived: sum of 3 quarters · filed 2026-08-19 | -$902.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $597.00K 10-Q/A · filed 2026-07-09 | $294.00K derived: sum of 2 quarters · filed 2026-07-09 | -$902.00K derived: sum of 3 quarters · filed 2026-07-09 | -$2.88M derived: sum of 4 quarters · filed 2026-07-09 |
| 2024-12-31 | -$303.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -$1.50M derived: sum of 2 quarters · filed 2026-06-01 | -$3.47M derived: sum of 3 quarters · filed 2026-06-01 | -$5.74M 10-K · filed 2026-06-01 |
| 2024-09-30 | -$1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$3.17M derived: sum of 2 quarters · filed 2025-11-19 | -$5.43M 10-Q · filed 2025-11-19 | |
| 2024-06-30 | -$1.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$4.24M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$2.26M 10-Q · filed 2025-05-20 | |||
| 2023-12-31 | $305.00K 10-K · filed 2025-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |